Scarica l'app Stockscreener
1.41
2.17%
0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.38
Aprire:
$1.41
Volume 24 ore:
7,863
Relative Volume:
0.10
Capitalizzazione di mercato:
$69.40M
Reddito:
$409.70K
Utile/perdita netta:
$-12.00M
Rapporto P/E:
-5.7669
EPS:
-0.2445
Flusso di cassa netto:
$-9.81M
1 W Prestazione:
+0.00%
1M Prestazione:
-13.50%
6M Prestazione:
+11.02%
1 anno Prestazione:
-3.42%
Intervallo 1D:
$1.39
$1.41
Intervallo di 1 settimana:
$1.29
$1.45
Portata 52W:
$1.13
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Nome
Medicinova Inc
Settore
Industria
Telefono
858-373-1500
Indirizzo
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.41 | 67.93M | 409.70K | -12.00M | -9.81M | -0.2445 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.44 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.78 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
742.84 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.68 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-10 | Iniziato | Maxim Group | Buy |
| 2019-03-25 | Ripresa | B. Riley FBR | Buy |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | Iniziato | Credit Suisse | Outperform |
| 2013-01-04 | Reiterato | Ladenburg Thalmann | Buy |
| 2012-05-24 | Downgrade | MLV & Co | Buy → Hold |
| 2011-10-18 | Reiterato | MLV Capital | Buy |
| 2011-06-22 | Iniziato | Global Hunter Securities | Buy |
| 2010-05-12 | Iniziato | Wedbush | Outperform |
| 2008-11-12 | Reiterato | Ladenburg Thalmann | Buy |
| 2008-05-15 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | Iniziato | Punk, Ziegel & Co | Buy |
Mostra tutto
Medicinova Inc Borsa (MNOV) Ultime notizie
Quarterly Recap: What is the next catalyst for MediciNova IncChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Trend Review: Is MediciNova Inc a stock for growth or value investorsWeekly Trading Summary & AI Forecasted Stock Moves - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can MediciNova Inc continue delivering strong returnsMarket Activity Recap & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Analyst Calls: Can AACG be recession proofJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MediciNova (MNOV) Price Target Increased by 11.11% to 10.20 - Nasdaq
Breakout Watch: What analysts say about MediciNova Inc stockGDP Growth & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Moves: Can MediciNova Inc continue delivering strong returns2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
MediciNova: Q4 Earnings Snapshot - Stamford Advocate
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MediciNova (NASDAQ:MNOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Aug PreEarnings: What analysts say about MediciNova Inc stockJuly 2025 Setups & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc. continue delivering strong returnsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - mfd.ru
MediciNova reports preliminary 2025 financial results in Tokyo filing By Investing.com - Investing.com India
MediciNova Financial Report: Q4 & Annual 2025 ResultsLoss & Revenue FiguresNews and Statistics - IndexBox
MediciNova reports preliminary 2025 financial results in Tokyo filing - Investing.com
4875.T MediciNova (JPX) JPY 254.00 pre-earnings 19 Feb: catalysts to watch - Meyka
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Update - MarketBeat
MediciNova (MNOV) Projected to Post Earnings on Wednesday - MarketBeat
Does MediciNova Inc. have strong fundamentalsRisk Management & Fast Exit and Entry Trade Guides - mfd.ru
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Here’s What Happened - Defense World
RSI Check: Is MediciNova Inc a stock for growth or value investorsQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Performance Recap: Is MediciNova Inc backed by strong institutional buyingLong Setup & Daily Profit Maximizing Tips - baoquankhu1.vn
MediciNova (MNOV) Price Target Increased by 28.57% to 9.18 - Nasdaq
Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study - streetwisereports.com
Trading Action: Is MediciNova Inc. a stock for growth or value investorsBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Biopharma Reaches 50% Enrollment in New ALS Drug Program - streetwisereports.com
MediciNova, Inc. (NASDAQ:MNOV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
D. Boral Capital Reaffirms “Buy” Rating for MediciNova (NASDAQ:MNOV) - Defense World
MediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
MediciNova reaches 50% enrollment milestone in ALS drug study By Investing.com - Investing.com Nigeria
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - The Manila Times
MediciNova reaches 50% enrollment milestone in ALS drug study - Investing.com
ALS patients gain wider access as MediciNova trial reaches 100 enrollees - stocktitan.net
MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Institution Moves: What are the risks of holding Real Messenger CorporationTrade Ideas & Consistent Return Investment Signals - baoquankhu1.vn
MNOVMediciNova Reports Third Quarter 2011 Results - ADVFN
Dip Buying: Can MediciNova Inc continue delivering strong returnsTrade Signal Summary & Short-Term High Return Ideas - baoquankhu1.vn
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th Int... - ADVFN
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average – Should You Sell? - Defense World
Price Action: How sensitive is MediciNova Inc to inflationMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Aug Patterns: Why MediciNova Inc. stock could benefit from AI revolutionMarket Growth Summary & Long-Term Capital Growth Strategies - Bộ Nội Vụ
Rate Hike: Why MediciNova Inc. stock could benefit from AI revolution2025 Trading Recap & Accurate Buy Signal Alerts - Bộ Nội Vụ
Columbia University/New York State Psychiatric Institute and MediciNova Report Preliminary Safety and Efficacy of Ibudilast in H - ADVFN
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - ADVFN
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence - ADVFN
Insider Buy: Will MediciNova Inc stock outperform value stocksJuly 2025 Action & Low Volatility Stock Recommendations - moha.gov.vn
Why MediciNova Inc. stock could benefit from AI revolutionMarket Trend Report & Expert Approved Momentum Trade Ideas - Улправда
Medicinova Inc Azioni (MNOV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
21.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):